Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

2.1K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
2.1K
Caspases01:24

Caspases

14.5K
Caspase, a family of cysteine proteases, serve as effectors in apoptosis. The ced3 gene in C.elegans was first identified to be involved in apoptosis. This gene encodes the ced-3 caspase that is similar to the interleukin-1-beta converting enzyme or ICE in mammals. In addition to apoptosis, caspases also function in the inflammatory response. Inflammatory caspases are essential in activating pro-inflammatory cytokines that recruit immune cells and block the replication of pathogens inside...
14.5K
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

58
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
58
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

161
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
161
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

106
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
106
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

65
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
65

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Seroprevalence of hepatitis C virus infection among individuals attending a private clinic in Luanda, Angola.

BMC infectious diseases·2026
Same author

HIV-1 late diagnosis in Cabo Verde: associated factors and implications for preventive strategies.

Frontiers in epidemiology·2026
Same author

Men who have sex with men newly diagnosed with HIV-1 in Portugal (2023-2024): a comparative analysis of transmission clusters between migrants and non-migrants.

Scientific reports·2026
Same author

HIV-1 late diagnosis: Strategies to overcome the misclassification of individuals acutely infected with HIV-1 as individuals diagnosed late.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same author

Emerging patterns in HIV integrase resistance.

AIDS (London, England)·2025
Same author

HIV multidrug class resistance prediction with a time sliding anchor approach.

Bioinformatics advances·2025

Related Experiment Video

Updated: Mar 22, 2026

Exploring Caspase Mutations and Post-Translational Modification by Molecular Modeling Approaches
05:56

Exploring Caspase Mutations and Post-Translational Modification by Molecular Modeling Approaches

Published on: October 13, 2022

1.9K

Glycidamide genotoxicity modulated by Caspases genes polymorphisms.

João Pereira de Lima1, Susana N Silva1, José Rueff1

  • 1Centre for Toxicogenomics and Human Health, Genetics, Oncology and Human Toxicology, NOVA Medical School/Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Rua Câmara Pestana, 6, 1150-082 Lisboa, Portugal.

Toxicology in Vitro : an International Journal Published in Association with BIBRA
|April 12, 2016
PubMed
Summary

This study investigated the link between genetic variations in apoptosis pathway genes and DNA damage caused by glycidamide, a metabolite of acrylamide. Certain gene variants, particularly in CASP8 and CASP10, were associated with increased DNA damage, suggesting a role for genetic susceptibility in acrylamide

Keywords:
AcrylamideApoptosisCancer susceptibilityCaspases genes polymorphismsDNA damageGlycidamide

More Related Videos

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K
A Rapid and Facile Pipeline for Generating Genomic Point Mutants in C. elegans Using CRISPR/Cas9 Ribonucleoproteins
08:37

A Rapid and Facile Pipeline for Generating Genomic Point Mutants in C. elegans Using CRISPR/Cas9 Ribonucleoproteins

Published on: April 30, 2018

8.2K

Related Experiment Videos

Last Updated: Mar 22, 2026

Exploring Caspase Mutations and Post-Translational Modification by Molecular Modeling Approaches
05:56

Exploring Caspase Mutations and Post-Translational Modification by Molecular Modeling Approaches

Published on: October 13, 2022

1.9K
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K
A Rapid and Facile Pipeline for Generating Genomic Point Mutants in C. elegans Using CRISPR/Cas9 Ribonucleoproteins
08:37

A Rapid and Facile Pipeline for Generating Genomic Point Mutants in C. elegans Using CRISPR/Cas9 Ribonucleoproteins

Published on: April 30, 2018

8.2K

Area of Science:

  • Environmental Toxicology
  • Molecular Biology
  • Genetics

Background:

  • Acrylamide (AA) is a dietary carcinogen, with its DNA-reactive metabolite being glycidamide (GA).
  • Apoptosis pathway genes play a crucial role in cellular response to DNA damage.
  • Polymorphisms in these genes may influence individual susceptibility to genotoxic effects.

Purpose of the Study:

  • To investigate the correlation between key polymorphic apoptosis genes (CASP7, CASP8, CASP9, CASP10, LTA, TNFRSF1B) and biomarkers of DNA damage.
  • To assess the role of pro-apoptotic effector proteins, encoded by polymorphic genes, in genotoxic effect yields.
  • To explore the relationship between genetic susceptibility and DNA damage induced by glycidamide.

Main Methods:

  • Exposure of whole blood cells from volunteers to glycidamide (GA).
  • Assessment of DNA damage using the sister chromatid exchange (SCE) assay and the comet assay.
  • Genotyping of volunteers for polymorphic genes involved in apoptosis pathways.

Main Results:

  • A significant association was observed between the CASP8 rs1035142 G>T polymorphism and the induction of SCE.
  • The CASP10 I522L polymorphism was found to be related to the percentage of tail DNA (% tail DNA) in the comet assay.
  • Several single nucleotide polymorphism (SNP)-SNP interactions between CASP8 and CASP10 were associated with % tail DNA.

Conclusions:

  • Genetic variations in apoptosis-related genes, specifically CASP8 and CASP10, may influence susceptibility to DNA damage induced by glycidamide.
  • Polymorphisms in apoptosis-inducing pathways could contribute to an individual's genetic predisposition to genotoxic effects.
  • This study provides a proof of concept for the role of polymorphic apoptosis genes in mediating DNA damage responses.